ELYM Eliem Therapeutics Inc

Price (delayed)

$8.32

Market cap

$242.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.53

Enterprise value

$137.23M

Highlights
Eliem Therapeutics's EPS has soared by 74% YoY and by 59% from the previous quarter
ELYM's net income has surged by 73% year-on-year and by 59% since the previous quarter
ELYM's quick ratio has soared by 60% YoY but it is down by 6% from the previous quarter
Eliem Therapeutics's equity has decreased by 9% YoY

Key stats

What are the main financial stats of ELYM
Market
Shares outstanding
29.09M
Market cap
$242.04M
Enterprise value
$137.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$14.53M
EBITDA
-$14.16M
Free cash flow
-$7.24M
Per share
EPS
-$0.53
Free cash flow per share
-$0.26
Book value per share
$3.84
Revenue per share
$0
TBVPS
$3.96
Balance sheet
Total assets
$109.33M
Total liabilities
$2.95M
Debt
$225,000
Equity
$106.38M
Working capital
$106.27M
Liquidity
Debt to equity
0
Current ratio
37.02
Quick ratio
35.6
Net debt/EBITDA
7.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-12.9%
Return on equity
-13.3%
Return on invested capital
-36.9%
Return on capital employed
-13.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELYM stock price

How has the Eliem Therapeutics stock price performed over time
Intraday
13.97%
1 week
19.03%
1 month
0.36%
1 year
204.76%
YTD
208.15%
QTD
17.02%

Financial performance

How have Eliem Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.84M
Net income
-$14.53M
Gross margin
N/A
Net margin
N/A
ELYM's net income has surged by 73% year-on-year and by 59% since the previous quarter
The operating income has soared by 64% YoY and by 51% from the previous quarter

Growth

What is Eliem Therapeutics's growth rate over time

Valuation

What is Eliem Therapeutics stock price valuation
P/E
N/A
P/B
2.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eliem Therapeutics's EPS has soared by 74% YoY and by 59% from the previous quarter
Eliem Therapeutics's equity has decreased by 9% YoY

Efficiency

How efficient is Eliem Therapeutics business performance
The return on assets has surged by 68% year-on-year and by 58% since the previous quarter
The company's return on equity has surged by 68% YoY and by 58% QoQ
ELYM's ROIC is up by 37% QoQ and by 36% YoY

Dividends

What is ELYM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELYM.

Financial health

How did Eliem Therapeutics financials performed over time
ELYM's quick ratio has soared by 60% YoY but it is down by 6% from the previous quarter
The current ratio has soared by 51% YoY but it has contracted by 4.9% from the previous quarter
ELYM's debt is 100% smaller than its equity
ELYM's debt to equity has shrunk by 100% YoY
ELYM's debt has dropped by 67% year-on-year and by 36% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.